Topic: checkpoint inhibitors
Eli Lilly is acquiring Armo Biosciences and its lead asset, a PEGylated form of the cytokine IL-10, for $1.6 billion.
The funding will advance its pipelines of synthetic cytokines, designed to improve immuno-oncology treatments.
FDA officials caused the delay by demanding to see additional CMC information before signing off on the study.
A combination of Checkmate's TLR9 agonist and Merck's Keytruda reversed PD-1 resistance in melanoma patients.
The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.
The combination of Incyte’s epacadostat and Merck & Co.’s Keytruda was supposed to pose a major threat to Bristol-Myers Squibb’s melanoma franchise.
Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.
AstraZeneca gains a source of bispecific and multispecific antibodies in return for $10 million upfront and up to $200 million in milestones.
Researchers are combining immunotherapies and attacking tumor defenses in efforts to improve checkpoint inhibitors.
Tempest Therapeutics is chasing Incyte and Bristol-Myers with what it thinks is a best-in-class IDO inhibitor.